DexCom, Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? DexCom, Inc. trades at $84.15 (market cap $31.86B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.47 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 2.3× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| DXCM | VTIP | |
|---|---|---|
Market Cap | $31.86B | $73.20B |
Volume | 3,607,070 | 2,511,360 |
Sector | Health | — |
52-Week High | $92.34 | $50.46 |
52-Week Low | $54.84 | $48.38 |
Typical Hold Time | 62 Days | 91 Days |
Enterprise Value | $31.32B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
VTIP trades at $48.46, showing minimal daily movement with a slight decline of 0.01%. Technical indicators present a mixed picture with bearish moving averages but bullish oscillators, including oversold RSI readings. The ETF focuses on short-term inflation-protected securities, offering protection against rising inflation while minimizing interest rate sensitivity. Recent institutional activity shows increased positions from firms like NewEdge Advisors and 55 North Private Wealth.
The outlook for VTIP remains tied to inflation dynamics and Federal Reserve policy. With inflation persisting above the 2% target, short-duration TIPS provide strategic hedging value. However, the fund faces risks from potential Fed policy shifts and real yield fluctuations. Current technical weakness suggests near-term pressure, but oversold conditions may present entry opportunities for inflation-conscious investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →